T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.07% |
| 2 | Healthcare | 18.73% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.39% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRSN
1901
DELISTED
Mersana Therapeutics
MRSN
| $758K | ﹤0.01% |
4,482
-1,111
| -20% | -$181K |
|
|
VMGAU
1902
DELISTED
VMG Consumer Acquisition Corp. Unit
VMGAU
| $758K | ﹤0.01% |
75,000
| – | – |
|
1903
Gogo Inc
GOGO
$377M
| $756K | ﹤0.01% |
62,305
+16,473
| +36% | +$250K |
|
|
AFAC
1904
DELISTED
Arena Fortify Acquisition Corp. Class A Common Stock
AFAC
| $756K | ﹤0.01% |
75,000
| – | – |
|
1905
Warrior Met Coal
HCC
$4.98B
| $754K | ﹤0.01% |
26,500
+5,663
| +27% | +$174K |
|
|
SGIIU
1906
DELISTED
Seaport Global Acquisition II Corp. Unit
SGIIU
| $754K | ﹤0.01% |
75,000
| – | – |
|
1907
The GEO Group
GEO
$4B
| $753K | ﹤0.01% |
97,789
-26,347
| -21% | -$194K |
|
1908
BOK Financial
BOKF
$8.85B
| $752K | ﹤0.01% |
8,452
-4,492
| -35% | -$389K |
|
|
HTO
1909
H2O America
HTO
$2.65B
| $744K | ﹤0.01% |
12,905
-1,653,133
| -99% | -$106M |
|
|
UTAAU
1910
DELISTED
UTA Acquisition Corporation Units
UTAAU
| $744K | ﹤0.01% |
73,500
| – | – |
|
1911
Medifast
MED
$130M
| $743K | ﹤0.01% |
6,853
-557
| -8% | -$79.8K |
|
1912
Aclaris Therapeutics
ACRS
$860M
| $742K | ﹤0.01% |
47,106
+9,077
| +24% | +$143K |
|
|
LAZR
1913
DELISTED
Luminar Technologies
LAZR
| $739K | ﹤0.01% |
6,755
+1,083
| +19% | +$129K |
|
1914
Spectrum Brands
SPB
$2.03B
| $739K | ﹤0.01% |
18,923
+5,958
| +46% | +$384K |
|
1915
AdaptHealth
AHCO
$760M
| $738K | ﹤0.01% |
39,257
+4,742
| +14% | +$97.5K |
|
1916
Eagle Bancorp
EGBN
$877M
| $737K | ﹤0.01% |
16,437
-3,427
| -17% | -$164K |
|
1917
BancFirst
BANF
$3.89B
| $736K | ﹤0.01% |
8,219
+1,303
| +19% | +$134K |
|
1918
Cinemark Holdings
CNK
$4.37B
| $736K | ﹤0.01% |
60,732
-2,467,342
| -98% | -$38.6M |
|
1919
Myriad Genetics
MYGN
$303M
| $735K | ﹤0.01% |
38,494
+5,160
| +15% | +$118K |
|
1920
NIO
NIO
$11.3B
| $735K | ﹤0.01% |
46,600
-7,900
| -14% | -$156K |
|
|
AVTA
1921
DELISTED
Avantax, Inc. Common Stock
AVTA
| $735K | ﹤0.01% |
37,964
-26,554
| -41% | -$534K |
|
1922
Construction Partners
ROAD
$6.9B
| $734K | ﹤0.01% |
27,946
+8,685
| +45% | +$228K |
|
1923
Petco
WOOF
$780M
| $734K | ﹤0.01% |
65,697
-2,622,933
| -98% | -$38.3M |
|
|
UNIT
1924
Uniti Group
UNIT
$2.31B
| $732K | ﹤0.01% |
105,195
+15,862
| +18% | +$147K |
|
|
EVBG
1925
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $730K | ﹤0.01% |
23,628
-1,144
| -5% | -$37.5K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.